• Angela Lorts
  • Timothy T. Cornell
  • Thomas P. Shanley


The health care provider faced with the management of a child with septic shock relies on a comprehensive understanding of the numerous disciplines embodied in the practice of pediatric critical care medicine. The child with septic shock may have simultaneous derangements in the function of virtually every system of the body including: cardiovascular, respiratory, immune, renal, coagulation, hepatic, metabolic and neurologic. The degree to which physiologic alterations are manifest in a given patient is variable and influenced by multiple host and non-host factors including: the developmental stage, the presence of co-morbidities, pathogen-related factors, and genetic influences on both the host inflammatory response as well as the response to pharmacologic agents, all combining to have a profound influence on outcome. The clinician must possess a systematic and multifaceted approach to these critically ill patients. The goal of this chapter is to provide a comprehensive description of the epidemiology, biology and pathophysiology (at both the cellular and organ level) of sepsis, as well as outlining the current principles of managing septic shock. It will be apparent that optimal management requires a strong working knowledge of cardiovascular physiology, infectious diseases, multiple organ interactions, immunity, coagulation, pharmacology, and the molecular biology of inflammation.


Septic Shock Severe Sepsis Systemic Inflammatory Response Syndrome Disseminate Intravascular Coagulation Pulmonary Capillary Wedge Pressure 

Suggested Readings

  1. Aird WC. Vascular bed-specific hemostasis: role of endothelium in sepsis pathogenesis. Crit Care Med. 2001;29:S28–34; discussion S34–5.PubMedCrossRefGoogle Scholar
  2. Annane D, Bellissant E, Bollaert PE, Briegel J, Keh D, Kupfer Y. Corticosteroids for severe sepsis and septic shock: a systematic review and meta-analysis. BMJ. 2004;329:480.PubMedCrossRefGoogle Scholar
  3. Arndt P, Abraham E. Immunological therapy of sepsis: experimental therapies. Intensive Care Med. 2001;27:S104–15.PubMedCrossRefGoogle Scholar
  4. Bernard GR, Vincent JL, Laterre PF, et al. Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med. 2001;344:699–709.PubMedCrossRefGoogle Scholar
  5. Beutler B. Signal transduction during innate and adaptive immunity. Biochem Soc Trans. 2001;29:853–9.PubMedCrossRefGoogle Scholar
  6. Bohrer H, Qiu F, Zimmermann T, et al. Role of NFkappaB in the mortality of sepsis. J Clin Invest. 1997;100:972–85.PubMedCrossRefGoogle Scholar
  7. Bone RC. Sepsis syndrome. New insights into its pathogenesis and treatment. Infect Dis Clin North Am. 1991;5:793–805.PubMedGoogle Scholar
  8. Bone RC, Sibbald WJ, Sprung CL. The ACCP-SCCM consensus conference on sepsis and organ failure. Chest. 1992;101:1481–3.PubMedCrossRefGoogle Scholar
  9. Briegel J, Forst H, Haller M, et al. Stress doses of hydrocortisone reverse hyperdynamic septic shock: a prospective, randomized, double-blind, single-center study. Crit Care Med. 1999;27:723–32.PubMedCrossRefGoogle Scholar
  10. Brierley J, Carcillo JA, Choong C, et al. Clinical practice parameters for hemodynamic support of pediatric and neonatal septic shock: 2007 update from the American College of Critical Care Medicine. Crit Care Med. 2009;37:666–88.PubMedCrossRefGoogle Scholar
  11. Brightbill HD, Modlin RL. Toll-like receptors: molecular mechanisms of the mammalian immune response. Immunology. 2000;101:1–10.PubMedCrossRefGoogle Scholar
  12. Calandra T, Baumgartner JD, Grau GE, et al. Prognostic values of tumor necrosis factor/cachectin, interleukin-1, interferon-alpha, and interferon-gamma in the serum of patients with septic shock. Swiss-Dutch J5 Immunoglobulin Study Group. J Infect Dis. 1990;161:982–7.PubMedCrossRefGoogle Scholar
  13. Ceneviva G, Paschall JA, Maffei FA, Carcillo JA. Hemodynamic support in fluid-refractory pediatric septic shock. Pediatrics. 1998;102:e19.PubMedCrossRefGoogle Scholar
  14. Dellinger RP, Carlet JM, Masur H, et al. Surviving Sepsis Campaign guidelines for management of severe sepsis and septic shock. Crit Care Med. 2004;32:858–73.PubMedCrossRefGoogle Scholar
  15. Dellinger RP, Levy MM, Carlet JM, et al. Surviving sepsis campaign: international guidelines for management of severe sepsis and septic shock: 2008. Crit Care Med. 2008;36:296–327.PubMedCrossRefGoogle Scholar
  16. Garrington TP, Johnson GL. Organization and regulation of mitogen-activated protein kinase signaling pathways. Curr Opin Cell Biol. 1999;11:211–8.PubMedCrossRefGoogle Scholar
  17. Guha M, Mackman N. LPS induction of gene expression in human monocytes. Cell Signal. 2001;13:85–94.PubMedCrossRefGoogle Scholar
  18. Gunn SR, Pinsky MR. Implications of arterial pressure variation in patients in the intensive care unit. Curr Opin Crit Care. 2001;7:212–7.PubMedCrossRefGoogle Scholar
  19. Ip YT, Davis RJ. Signal transduction by the c-Jun N-terminal kinase (JNK) – from inflammation to development. Curr Opin Cell Biol. 1998;10:205–19.PubMedCrossRefGoogle Scholar
  20. Karin M, Delhase M. The I kappa B kinase (IKK) and NF-kappa B: key elements of proinflammatory signalling. Semin Immunol. 2000;12:85–98.PubMedCrossRefGoogle Scholar
  21. Keh D, Sprung CL. Use of corticosteroid therapy in patients with sepsis and septic shock: an evidence-based review. Crit Care Med. 2004;32:S527–3.PubMedCrossRefGoogle Scholar
  22. Kumar A, Krieger A, Symeoneides S, Parrillo JE. Myocardial dysfunction in septic shock: Part II. Role of cytokines and nitric oxide. J Cardiothorac Vasc Anesth. 2001;15:485–511.PubMedCrossRefGoogle Scholar
  23. Levi M, de Jonge E, van der Poll T. Rationale for restoration of physiological anticoagulant pathways in patients with sepsis and disseminated intravascular coagulation. Crit Care Med. 2001;29:S90–4.PubMedCrossRefGoogle Scholar
  24. Lin MT, Albertson TE. Genomic polymorphisms in sepsis. Crit Care Med. 2004;32:569–79.PubMedCrossRefGoogle Scholar
  25. Marik PE, Mohedin M. The contrasting effects of dopamine and norepinephrine on systemic and splanchnic oxygen utilization in hyperdynamic sepsis. JAMA. 1994;272:1354–7.PubMedCrossRefGoogle Scholar
  26. Marik PE, Zaloga GP. Early enteral nutrition in acutely ill patients: a systematic review. Crit Care Med. 2001;29:2264–70.PubMedCrossRefGoogle Scholar
  27. Marshall JC, Maier RV, Jimenez M, Dellinger EP. Source control in the management of severe sepsis and septic shock: an evidence-based review. Crit Care Med. 2004;32:S513–26.PubMedCrossRefGoogle Scholar
  28. McGilvray ID, Rotstein OD. Role of the coagulation system in the local and systemic inflammatory response. World J Surg. 1998;22:179–86.PubMedCrossRefGoogle Scholar
  29. Meduri GU. New rationale for glucocorticoid treatment in septic shock. J Chemother. 1999;11:541–50.PubMedGoogle Scholar
  30. Medzhitov R, Janeway Jr C. Innate immunity. N Engl J Med. 2000;343:338–44.PubMedCrossRefGoogle Scholar
  31. Opal SM, DePalo VA. Anti-inflammatory cytokines. Chest. 2000;117:1162–72.PubMedCrossRefGoogle Scholar
  32. Parker MM, Hazelzet JA, Carcillo JA. Pediatric considerations. Crit Care Med. 2004;32:S591–4.PubMedCrossRefGoogle Scholar
  33. Proulx F, Fayon M, Farrell CA, Lacroix J, Gauthier M. Epidemiology of sepsis and multiple organ dysfunction syndrome in children. Chest. 1996;109:1033–7.PubMedCrossRefGoogle Scholar
  34. Pulmonary Artery Catheter Consensus conference: consensus statement. Crit Care Med. 1997;25:910–25.Google Scholar
  35. Raggio MJ, Morris PE. Drotrecogin alfa. Drugs Today. 2004;40:517.PubMedCrossRefGoogle Scholar
  36. Reeves JH, Butt WW, Shann F, et al. Continuous plasmafiltration in sepsis syndrome. Plasmafiltration in Sepsis Study Group. Crit Care Med. 1999;27:2096–104.PubMedCrossRefGoogle Scholar
  37. Rivers E, Nguyen B, Havstad S, et al. Early goal-directed therapy in the treatment of severe sepsis and septic shock. N Engl J Med. 2001;345:1368–77.PubMedCrossRefGoogle Scholar
  38. Strieter RM, Belperio JA, Kelley D, Sakkour A, Keane MP. Innate immune mechanisms triggering lung injury. In: Wong HR, Shanley TP, editors. Molecular biology of acute lung injury. Norwell: Kluwer Academic Publishers; 2001. p. 17–33.CrossRefGoogle Scholar
  39. Vincent JL, Zhang H, Szabo C, Preiser JC. Effects of nitric oxide in septic shock. Am J Respir Crit Care Med. 2000;161:1781–5.PubMedGoogle Scholar
  40. Wong HR, Shanley TP. Signal transduction pathways in acute lung injury: NF-κB and AP-1. In: Wong HR, Shanley TP, editors. Molecular biology of acute lung injury. Norwell: Kluwer Academic Publishers; 2001. p. 1–16.CrossRefGoogle Scholar

Copyright information

© Springer-Verlag London Limited 2012

Authors and Affiliations

  • Angela Lorts
    • 1
  • Timothy T. Cornell
    • 2
  • Thomas P. Shanley
    • 2
  1. 1.Pediatric Cardiology, Department of PediatricsUniversity of Cincinnati College of Medicine, Cincinnati Children’s Hospital Medical CenterCincinnatiUSA
  2. 2.Pediatric Critical Care Medicine, Department of PediatricsUniversity of Michigan, C.S. Mott Children’s HospitalAnn ArborUSA

Personalised recommendations